Gut is a leading international journal in gastroenterology and hepatology and has an established reputation for publishing first class clinical research of the alimentary tract, the liver, biliary tree and pancreas. Gut delivers up-to-date, authoritative, clinically oriented coverage in all areas of gastroenterology and hepatology. Regular features include articles by leading authorities describing novel mechanisms of disease and new management strategies, both diagnostic and therapeutic, likely to impact on clinical practice within the foreseeable future.
Our new online collection highlights all research relating to the COVID-19 pandemic published by Gut, Frontline Gastroenterology and BMJ Open Gastroenterology. It is updated regularly as new articles are published.
Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in IBD
To cite: Khan N, Mahmud N, Trivedi C, et al. Gut 2021;70:1657-1664.
Read the full article here: link
Objective: Our aim was to explore the risk of infection with all classes of inflammatory bowel disease (IBD) medications and the impact of these medications on the disease course in a nationwide cohort of patients with IBD.
Conclusions: VDZ and corticosteroid were associated with an increased risk of SARS-CoV-2 infection. Except for corticosteroids no medications including mesalazine were associated with an increased risk of severe COVID-19.